Welgus Howard G. 4
4 · Arcutis Biotherapeutics, Inc. · Filed May 5, 2026
Research Summary
AI-generated summary of this filing
Arcutis (ARQT) Director Howard Welgus Sells 7,144 Shares
What Happened
Howard G. Welgus, a director of Arcutis Biotherapeutics, sold 7,144 shares in open-market transactions on May 1, 2026. The weighted-average sale price was $22.99, for total proceeds of approximately $164,220. This was a sale (not a purchase or option exercise).
Key Details
- Transaction date: May 1, 2026; Form 4 filed May 5, 2026 (timely filing).
- Sale type/code: S (sale) — open market or private sale.
- Price: weighted average $22.99; actual trade prices ranged $22.79–$23.25 (footnote states per-price breakdown available on request).
- Total shares sold: 7,144; total proceeds ≈ $164,220.
- Shares owned after transaction: not specified in the supplied filing.
- Footnotes: Transaction was made pursuant to a 10b5-1 trading plan adopted March 11, 2025, with a plan end date of May 29, 2026. The filing includes a commitment to provide exact per-price quantities if requested.
Context
This sale was executed under a pre-established 10b5-1 plan, which typically schedules trades in advance and can indicate the sale was routine rather than a real‑time signal of the insider’s view. Sales are common for insiders for diversification or liquidity reasons; they are less informative than purchases about an insider’s confidence in the company.
Insider Transaction Report
Form 4
Welgus Howard G.
Director
Transactions
- Sale
Common Stock
[F1][F2]2026-05-01$22.99/sh−7,144$164,220→ 32,600 total
Footnotes (2)
- [F1]The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026.
- [F2]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $22.79 to $23.25, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Signature
/s/ Latha Vairavan, as Attorney-in-Fact for Howard G. Welgus|2026-05-05